News About: Pharm. Industry
Hanmi to patent human growth hormone in liquid composite.
Hanmi has registered a patent for a stabilized liquid form of human growth hormone composite in Korea, which was developed by 2,850 million won of investment. The discovery showed not to use conventional preservatives...
NHI to reimburse additional indication of Aricept.
The NHI reimbursement for Aricept, an Eisai Korea drug in an additional indication of vascular schizophrenia to Alzheimer disease has been approved according to the revised ordinance dated on Jan. 31 titled "Standards...
Drug industry to strengthen warranty in wholesale business.
In consequences to the recent serial outbreaks of wholesaler's bankruptcies the pharmaceutical companies showed a resuming movement for the requests of more warranties in the business deals with the wholesalers, proba...
SNU hospital tender amid hot competition.
The SNU hospital invited a public tender for the purchase of drugs on Feb. 6 and the total 20 groups have been failed in the tender amid a powerful position shown by Burim and Gaeseong wholesale companies. The 20 grou...
Hallim to develop a modified new anti-hypertension drug.Hallim pharmaceutical company has succeeded in the development of a new modified anti-hypertension drug called Naidipin, formulating with amlodipine nicotinate.
Naidipin sho...
|
North Korean health/medical representatives to visit Novartis.A North Korean health and medical related representative group including Health Minister Kim Hak-soo, and other experts visited the head office of Novartis in Switzerland on Jan...
|
AZ Korea to hold successful symposium on Seroquel.AstraZeneca Korea took a symposium for the celebration of the 5th anniversary of launching Seroquel (quetiapine) into the Korean market on Feb. 4 by inviting about 80 psychiatri...
|
Sudo to sign joint A1 flu vaccine development with a US firm.Sudo pharmaceutical company signed an agreement for the joint development of A1 flu vaccine at Seoul Press Center with MediVas Bio venture company of America.
The agreement d...
|
NHI to reimburse Reminyl for additional indications from Feb.
The NHI reimbursement for the additional indications of Reminyl, an anti-schizophrenia drug, will be effected from Feb. 1 covering the Alzheimer disease patients with cerebral vascular conditions according to the revi...
Green Cross joint anti-cancer drug research with MD Anderson Cancer Center.
Mokam Bio Engineering Research Institute, an affiliated institute of Green Cross, agreed a joint research and development with MD Anderson Cancer Center in the United States for Greenstatin, a novel anti-angiogenesis ...
